Merck
CN
Search Within
文件类型

274-102-0

应用筛选条件
关键词:'274-102-0'
显示 1-30 共 40 条结果 关于 "274-102-0" 范围 技术文档
Protocol: Rat/Mouse C-Peptide 2 ELISA Kit
µl 91 91% 111 96% 5 µl 44 88% 59 102% Rat 20 µl 491
Protocol- EZRMCP2-21K
S am pl e 2 2 20 0 pM 20 0 pM 40 0 pM 40 0 pM 80 0 pM
Product Information Sheet-11333062910
Fab fragments 150 U, 200 μl 11 093 274 910 Digoxigenin-3-O-methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccinimide ester 5 mg 11 333 054 001 ABTS 2 g 10 102 946 001 Blocking Reagent 50 g 11 096
Examination of Non-Specifically Bound Proteins and Peptides Following Depletion of Twenty High Abundance Proteins from Human Plasma
217 3 2071 3 215 2 207 3 257 3 483 5 IPI00399007 Hypothetical protein DKFZp 250 4 269 3 274 5 347 4 156 4 102 3 253 4 352 7 IPI00784998 Hypothetical protein DKFZp 139 3
Protein Tyrosine Phosphatases- Potential Roles in Disease
d e r : 1 . 8 0 0 . 3 2 5 . 3 0 1 0 ( U S ) T e c h n i c a l S
Product Information Sheet - CS0150
receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem., 274, 8335-8343 (1999). 6. Schooler, K., and Wiley, H.S., Ratiometric assay of epidermal growth factor
Product Information Sheet - CS0630
protective activity against oxidative stress/ tumor necrosis factor α by phosphorylation., J. Biol. Chem. 274, 18947-18956 (1999). 8. Garrido, C., et al., HSP27 inhibits cytochrome c- dependent activation
Immunogenicity Testing Guidelines
Methods 333(102): 1-9. 11. Shankar G, Shores E, Wagner C, and Mire-sluis AR. (2006) Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 24(6): 274-80. 12
Exploring the RNA world: An introduction to genome-wide analysis of RNA-protein interactions using RNA-binding protein immunoprecipitation (RIP)
method for the in vivo isolation of ribonucleoprotein complexes. Methods Mol Biol 118: 265-274. 17. Tenenbaum SA, Carson CC, Lager PJ, Keene JD (2000) Identifying mRNA subsets in
Product Information Sheet - CS0080
receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem., 274, 8335-8343 (1999). 6. Schooler, K., and Wiley, H.S. Ratiometric assay of epidermal growth factor
Calbiochem Biologics 32.2
Process - IGF-1 + IGF-1 0– 2– 4– 6– 0– 2– 4– 6– [m AU x 1 06 ] [m AU x 1 06 ]
Calbiochem Biologics 31.1
595) 0 13 25 51 102 203 407 814 1628 (Units) 17 34 69 138 275 550 1100 2200 (pg) R2=0.999 Chk2 Activity (Abs 450/595)
p53 And Related Products
0.0 0 300 600 900 1200 1500 p53 (ng/ml) Ab so rb an ce ( 49 0- 63 0 nm ) ELISA: Abs 450 nm 0.156 0.265 0.336 0.433 0.625 0.993 1.57 2.72 Phospho-p53 (Ser15) units/test 0
Product Information Sheet - CS0140
receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem., 274, 8335-8343 (1999). 6. Schooler, K., and Wiley, H.S. Ratio metric assay of epidermal growth factor
Product Information Sheet - CS0640
protective activity against oxidative stress/ tumor necrosis factor α by phosphorylation., J. Biol. Chem. 274, 18947-18956 (1999). 8 8. Garrido, C., et al., HSP27 inhibits cytochrome c- dependent
Antibody Sourcebookル Sixth Edition
Anti-Clathrin Heavy Chain Mouse mAb (X22) IB, IF, IP bovine, human, mouse, rat CP45 100 µl €274 Anti-CLOCK (11-�0) Rabbit pAb IB, IH hamster, human, mouse, rat 2��170 200 µl €�15 Anti-Coagulation Factor
Biologics 31.1
595) 0 13 25 51 102 203 407 814 1628 (Units) 17 34 69 138 275 550 1100 2200 (pg) R2=0.999 Chk2 Activity (Abs 450/595)
Product Information Sheet - PP0500
. et al., Electrophoresis, 19, 918-27 (1998). 33. Jimenez-Asensio, J., et al., J. Biol. Chem., 274, 32287-94 (1999). 34. Jeno, P., et al., Anal. Biochem., 224, 75-82 (1995). 35. Xu, S-Q et al.
Chrombook (WEB-Version)
1.51333.0001 291 1.51343.0001 274 1.51345.0001 274 1.51349.0001 274 1.51351.0001 274 1.51353.0001 274 1.51354.0001 274 1.51355.0001 274 1.51356.0001 274 1.51378.0003 294 1.51384.0001
Calbiochem Biologics 30.2
409445 Cat. No. 251405 1 mg € 167 Cat. No. 569390 100 µg € 352 Cat. No. CP06 100 µg € 274 Cat. No. 654160
JULABO Catalog 2011 en
+63 +230 +292 +184 +210 Fire point °C +142 >+162 >+112 +274 +334 +212 +235 Viscosity, kinetic mm²/s 0 °C 5 at 0 °C <51.5 at 20 °C 84 at 20 °C 122.45 at 20 °C 47.1
Research Focus - Volume 5 2012
103 : 691. Craig, A.L., et al. Biochem. J. 1999; 342: 133. Zaika, A., et al. J. Biol. Chem. 1999; 274: 27474. Freedman, D.A., and Levine, A.J. Mol. Cell Biol. 1998; 18: 7288. Sigalas, I., et al. Nat. Med
User Guide-HIFN130K
Preparation of Standards Standard IFNε (pg/mL) IFNα2 (pg/mL) IFNɣ (pg/mL) Standard 1 274 34 4.1 Standard 2 823 103 12 Standard 3 2,469 309 37 Standard 4 7,407 926 111 Standard 5 22,222
User Guide
Preparation of Standards Standard IFNε (pg/mL) IFNα2 (pg/mL) IFNɣ (pg/mL) Standard 1 274 34 4.1 Standard 2 823 103 12 Standard 3 2,469 309 37 Standard 4 7,407 926 111 Standard 5 22,222
User Guide
14 Preparation of Standards Standard IFNε (pg/mL) IFNα2 (pg/mL) IFNɣ (pg/mL) Standard 1 274 34 4.1 Standard 2 823 103 12 Standard 3 2,469 309 37 Standard 4 7,407 926 111 Standard 5 22,222
JAK/STAT Signaling Research Focus
transcription. 10 mg 25 mg InSolution™ STAT3 Inhibitor VI, S3I-201 573130 A 50 mM (5 mg/274 µL) solution of STAT3 Inhibitor VI, S3I-201 (Cat. No. 573102) in DMSO. 5 mg STAT3 Inhibitor
Calbiochem Biologics 32.4
Ref.: Hausser, A ., et al . 2001 . FEBS Lett. 492, 39; Hausser, A ., et al . 1999 . J. Biol. Chem. 274, 9258; Nishikawa, K ., et al . 1998 . J. Biol. Chem. 273, 23126; Rennecke
Calbiochem Biologics 33.1
. Specific activity: ≥1 µmol/min/mg protein. Purity: ≥95% by SDS-PAGE. Cat. No. 444148 25 mg €274 HCV NS3/4A Protease, Recombinant, E. coli A recombinant, human Hepatitis C Virus (HCV) protease
Packaging portfolio for chemicals: A selection of Data Sheets
: HDPE Nominal volume: 10 L Weight: min. 395 g Height: 293 mm Width: 179 mm Length: 274 mm Mouth: S85 Opening: 72.2 mm Tightness-proven closure Name: S85 Material: PP
Bioreactor Systems for Bone Tissue Engineering
the cells within the scaffold at a defined frequency, amplitude, intensity, and pulse duration. 274 RAUH ET AL. http://www.liebertonline.com/action/showImage?doi=10.1089/ten.teb.2010.0612&iName
1/2